In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced ...

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program. Replimune Group received a complete ...

Telix contributes end-to-end radiopharma capabilities, including isotope selection, radiochemistry, scalable manufacturing, and a global distribution network tailored to short half-life radioisotopes.

Incorporating patient voice early can reduce burden through fewer visits, simpler procedures, and selective decentralization while maintaining trial objectives. Engagement failures commonly stem from ...

Regeneron and Telix have entered a radiopharmaceutical collaboration worth up to $2.1 billion in milestones, combining antibody-based targeting with isotope delivery to develop next-generation ...

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...

The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...